Irene Griswold-Prenner is the founder of Nitrase Therapeutics. Latest round: Series A. Backed by innova, Abbie Ventures, Ementia Discovery.
Irene Griswold-Prenner is the Founder, CEO, and CSO of Nitrase Therapeutics, a biotechnology company developing first-in-class antibody therapeutics for Parkinson's disease and other synucleinopathies. She is a scientist-turned-entrepreneur who discovered a new class of enzymes and persisted through extensive VC outreach to secure seed funding before raising a $45M Series A. Her work focuses on blocking the propagation of pathogenic nitrated synuclein to delay disease progression in preclinical models.
Full founder directory · Investor directory · Company funding database · Fundraising library